ABSTRACT
Objective Preliminarily discussing the effects of VEGF and SOX2 on metastasis and progno-sis of squamous cell lung carcinoma(SCLC).Methods Using immunohistochemical method to detect 47 cases of pulmonary squamous cell carcinoma and 30 cases of para-carcinoma tissue in the expression of VEGF and SOX2, using statistical methods to analyze the expression of VEGF and SOX2 and the relationship between clinical parame-ters and its relationship with prognosis. Results The positive expression rates of VEGF,SOX2 in SCLC tissues were higher than adjacent normal tissues.There was a significant correlation between VEGF and SOX2 expression. VEGF expression was associated with lymph node metastases and TNM stage.SOX2 expression was associated with tumor differentiation and lymph node status.Survival analysis indicated that VEGF(+)/SOX2(+)patients had the worst prognosis.Furthermore,multivariate analysis suggested that tumor diameter and lymph node metastases were independent prognostic factors for SCLC. Conclusion The expression of VEGF was positively correlated with lymph node metastasis and clinical stage,the expression of SOX2 was positively correlated with tumor differentia-tion degree and lymph node metastasis,and high expression of VEGF and SOX2 may indicate lung squamous can-cer patients with poor prognosis.
ABSTRACT
Abstrac Objective:To investigate the clinical efficacy of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) in the treatment of squamous-cell lung cancer patients with EGFR mutations. Methods:We screened out seven patients who were diag-nosed with EGFR mutations and received EGFR-TKIs, such as gifitinib or erlotinib, from 2,317 squamous-cell lung cancer patients treat-ed at the Beijing Chest Hospital from January 2010 to July 2016. Results:After using EGFR-TKIs, the objective response rate was 42.9%, the disease control rate was 100%, and the median progression-free survival was 6.1 months. Conclusion:EGFR-TKIs exert a certain clinical curative effect on patients with EGFR mutations in squamous-cell lung cancer. However, given that only seven cases are pre-sented in this research group, more cases are needed for further research to verify the above conclusion.
ABSTRACT
Objective: To explore the clinical value of postoperative chemotherapy for combined small cell and squamous cell lung cancer. Methods: The data of 50 patients with combined small cell and squamous cell lung cancer who underwent radical surgery in Tianjin Chest Hospital between May 2004 and April 2012 were collected and a retrospective study of the clinical features was performed. The patients were divided into post-operative chemotherapy group and no-chemotherapy group. The Kaplan-Meier method was used to calculate the survival rate and depict the survival curves. The log-rank test was used to compare the survival and perform the univariate analysis of prognostic factors. The COX regression model was used to analyze the multivariate survival factors. Results: For fifty patients with combined small cell and squamous cell lung cancer, the progression-free survival (PFS) ranged from 2 to 40 months (median PFS: 14 months). The Kaplan-Meier survival curves revealed that the PFS was affected by the tumor location (left or right; P = 0.010), lymph node metastasis (yes or no; P = 0.013), post-operative chemotherapy (yes or no; P = 0.009) and N staging (P = 0.001). The COX multivariate analysis showed that N staging (hazard ratio: 5.460, 95% confidence interval: 2.007-14.852, P = 0.001) and post-operative chemotherapy (hazard ratio: 0.317, 95% confidence interval: 0.126-0.800, P = 0.015) were independent prognostic factors for PFS of the patients. Conclusion: The combined small cell and squamous cell lung cancer is a special subtype of small cell lung cancer. The preoperative examination should be improved and the pre-operative evaluation should be performed seriously according to TNM staging. For early stage patients with surgical indications, post-operative chemotherapy may improve the prognosis.
ABSTRACT
A 68-year-old man with Guillain-Barre syndrome after the resection of right upper lobe for squamous cell lung cancer is presented. He developed a sudden, symmetric, extremity weakness, respiratory insufficiency, and sensory ataxia on postoperative day 6. He was intubated emergently and placed on a ventilator. Electrodiagnostic studies were performed on days 2, 20, and 40 following the onset of weakness. Motor nerve conduction abnormalities were the predominant findings. Prolonged motor distal latencies, temporal dispersion, and partial motor conduction blocks were present and formed the diagnostic features of Guillain-Barre syndrome. With supportive care and additive use of intravenous immunoglobulin, the illness resolved 6 weeks later after the onset of weakness.
Subject(s)
Aged , Humans , Ataxia , Extremities , Guillain-Barre Syndrome , Immunoglobulins , Lung Neoplasms , Lung , Neural Conduction , Respiratory Insufficiency , Ventilators, MechanicalABSTRACT
A 68-year-old man with Guillain-Barre syndrome after the resection of right upper lobe for squamous cell lung cancer is presented. He developed a sudden, symmetric, extremity weakness, respiratory insufficiency, and sensory ataxia on postoperative day 6. He was intubated emergently and placed on a ventilator. Electrodiagnostic studies were performed on days 2, 20, and 40 following the onset of weakness. Motor nerve conduction abnormalities were the predominant findings. Prolonged motor distal latencies, temporal dispersion, and partial motor conduction blocks were present and formed the diagnostic features of Guillain-Barre syndrome. With supportive care and additive use of intravenous immunoglobulin, the illness resolved 6 weeks later after the onset of weakness.
Subject(s)
Aged , Humans , Ataxia , Extremities , Guillain-Barre Syndrome , Immunoglobulins , Lung Neoplasms , Lung , Neural Conduction , Respiratory Insufficiency , Ventilators, MechanicalABSTRACT
PURPOSE: We evaluated retrospectively the outcomes of inoperable squamous cell lung cancer patients treated with radiotherapy to find out prognostic factors affecting survival. MATERIALS AND METHODS: Four hundred and eleven patients diagnosed as squamous cell lung cancer between November 1988 and December 1997 were the basis of this analyses. The planned dose to the gross tumor volume was ranged from 30 to 70.2 Gy. Chemotherapy was combined in 72 patients (17.5%) with the variable schedule and drug combination regimens. Follow-up period ranged from 1 to 113 months with the median of 8 months and survival status was identified in 381 patients (92.7%). Overall survival rate was calculated using the Kaplan-Meier method. RESULTS: Age ranged from 23 years to 83 years with the median 63 years. The male to female ratio was about 16:1. For all 411 patients, the median overall survival was 8 months and the 1-year survival rate (YSR), 2-YSR, and 5-YSR were 35.6%, 12.6%, and 3.7%, respectively. The median and 5-YSR were 29 months and 33.3% for Stage IA, 13 months and 6.3% for Stage IIIA, and 9 months and 3.4% for Stage IIIB, respectively( p=0.00). The median survival by treatment aim was 11 months in radical intent group and 5 months in palliative, respectively ( p=0.00). Of 344 patients treated with radical intent, median survival of patients (N=247) who received planned radiotherapy completely was 12 months while that of patients (N=97) who did not was 5 months ( p=0.0006). In the analyses of the various prognostic factors affecting to the survival outcomes in 247 patients who completed the planned radiotherapy, tumor location, supraclavicular LAP, SVC syndrome, pleural effusion, total lung atelectasis and hoarseness were statistically significant prognostic factors both in the univariate and multivariate analyses while the addition of chemotherapy was statistically significant only in multivariate analyses. The acute radiation esophagitis requiring analgesics was appeared in 49 patients (11.9%) and severe radiation esophagitis requiring hospitalization was shown in 2 patients (0.5%). The radiation pneumonitis requiring steroid medication was shown in 62 patients (15.1%) and severe pneumonitis requiring hospitalization was occurred in 2 patients (0.5%). During follow-up, 114 patients (27.7%) had progression of local disease with 10 months of median time to recur (range : 1~87 months) and 49 patients (11.9%) had distant failure with 7 months of median value (range : 1~52 months). Second malignancy before or after the diagnosis of lung cancer was appeared in 11 patients. CONCLUSION: The conventional radiotherapy in the patients with locally advanced squamous cell lung cancer has given small survival advantage over supportive care and it is very important to select the patient group who can obtain the maximal benefit and to select the radiotherapy technique that would not compromise the life quality in these patients.
Subject(s)
Female , Humans , Male , Analgesics , Appointments and Schedules , Diagnosis , Drug Therapy , Esophagitis , Follow-Up Studies , Hoarseness , Hospitalization , Lung Neoplasms , Lung , Multivariate Analysis , Neoplasms, Second Primary , Pleural Effusion , Pneumonia , Pulmonary Atelectasis , Quality of Life , Radiation Pneumonitis , Radiotherapy , Retrospective Studies , Survival Rate , Tumor BurdenABSTRACT
The nephrotic syndrome that occurs in the absence of renal vein thrombosis, amyloidosis, neoplastic infiltration of the kidneys is an unusual but a well recognized paraneoplastic syndrome. The most frequently reported neoplasms associated with nephrotic syndrome are Hodgkin's disease and various carcinomas. The most common renal lesions are membranous glomerulonephritis(MGN) associated with carcinomas and minimal change lesions associated with Hodgkin's disease. Approximately 40% to 45% of patients clinically manifest the MGN symptoms prior to the diagnosis of the tumor, 40% simultaneously with the tumor and the remaining 15% to 20% following the tumor. Therefore, evaluating the underlying malignancy in patients with MGN is important. Here we report a patient with squamous cell lung cancer, which was detected 12 months after a MGN had been diagnosed, with a review of the relevant literature.
Subject(s)
Humans , Amyloidosis , Diagnosis , Glomerulonephritis, Membranous , Hodgkin Disease , Kidney , Lung Neoplasms , Lung , Nephrotic Syndrome , Paraneoplastic Syndromes , Renal Veins , ThrombosisABSTRACT
Bowen's disease is well known that it can be associated with visceral malignancy. However, the relationship of Bowen's disease to internal malignancy remains controversial. We report a case of a 51-year-old male with multiple Bowen's diseases accompanied with arsenical keratosis and squamous-cell lung cancer.
Subject(s)
Humans , Male , Middle Aged , Bowen's Disease , Keratosis , Lung Neoplasms , LungABSTRACT
BACKGROUND: Nucleolar organizer regions(NORs) are chromosomal segments encoding for ribosomal RNA and associated with argyrophilic nonhistone protein. Ribosomal RNA genes ultimately direct ribosome and protein synthesis, and it has been suggested the numbers of NORs detected in the cell may reflect nuclear and cellular activity. This study was performed to evaluate the applicability of AgNORs to the diagnosis of squamous cell carcinoma of the lung. METHOD: The one step silver methods(AgNORs) was used to stain NORs in the routinely processed, formalin fixed, paraffin embedded sections of 36 cases of squamous cell carcinoma of the lung obtained by surgical resection of primary tumor. In each specimen, 100 tumor cells and 100 normal cells adjacent to the tumor chosen at random were examined under an oil immersion lens at a magnification of X1000. The mean number of AgNORs per nucleus was calculated for each specimen. RESULTS: The mean number of AgNORs per nucleus(mAgNORs) of normal bronchial epithelium and squamous cell carcinoma of the lung was 1.74+/-0.25 and 4.05+/-0.80, respectively. The difference of mAgNOR between normal and tumor tissue was statistically significant(p<0.001). There was no statistical difference among tumors of different stages. The difference of mAgNOR between normal and tumor tissue was statistically significant in each TNM stage(p<0.05). CONCLUSION: Mean AgNOR count may be used as a useful marker for the differential diagnosis of benignancy and malignancy, and proliferative activity of the cell in squamous cell carcinoma of the lung. But there was no statistical difference in mean AgNOR count among tumors of different surgical stages. Further studies for the application of mAgNORs to the diagnosis of other histologic types and cytologic specimens of the lung cancer are needed.